Finasteride is the most-prescribed hair-loss drug in the world. It's also the most discussed, and some of that discussion is more heat than data. Here's an honest breakdown — what the trials found, what post-marketing surveillance has added, and what we'd tell a friend before they started.
Three categories show up in trials: decreased libido, erectile dysfunction, and ejaculatory changes (reduced volume or delayed ejaculation). In the original 5-year Propecia trials, combined sexual side effects affected roughly 3–4% of men on finasteride versus 2% on placebo — so the drug-attributable rate is around 1–2%. Most cases were mild and resolved on stopping.
What the numbers mean in practice: if you put 100 men on finasteride, 1 to 2 will notice a sexual symptom they reasonably attribute to the drug. A slightly higher number will notice something but can't be sure. The large majority will feel no difference.
Original trials didn't track mood systematically. Post-marketing surveillance and observational studies since then have identified a small signal for depression and anxiety. FDA labeling now includes mood changes as a potential effect. Absolute risk in otherwise healthy men appears to be low, but it's not zero. We ask about baseline mood on intake and follow up if anything changes.
Breast tenderness or enlargement. Rare — under 1% in clinical trials. When it happens it usually resolves on stopping the medication. If a lump develops that feels hard or asymmetric, that's a reason to pause finasteride and get an in-person evaluation.
Post-finasteride syndrome (PFS) describes persistent symptoms — sexual, cognitive, and mood — that continue after stopping the drug. It's controversial in the medical literature. Some biological mechanisms have been proposed (changes to neurosteroid metabolism, androgen receptor expression), but the evidence is mixed and the syndrome is not universally accepted.
Our honest position: it's rare, poorly understood, and real for the men who experience it. We counsel about it openly. If you have a history of significant anxiety or depression, we discuss whether finasteride is the right choice. If you develop persistent symptoms, we'd rather you pause the medication and we investigate than have you continue pushing through.
Finasteride lowers PSA (prostate-specific antigen) by about 50%. This matters if you're over 50 or otherwise planning prostate cancer screening — your lab will need to know you're on finasteride so they can interpret the PSA correctly (usually by doubling the value). Older data raised a concern about finasteride and high-grade prostate cancer; subsequent reanalyses largely attributed this to detection bias. Current consensus is that finasteride does not increase overall prostate cancer mortality, but a PSA conversation with your PCP before starting is still the right move if you're over 50.
For the large majority of men who stop finasteride because of a side effect, symptoms resolve within days to weeks. Hair gains also reverse — within 6–12 months of stopping, the hair you kept from treatment will generally be lost again. That's the trade-off finasteride asks you to accept: ongoing treatment for ongoing benefit.
Other hair-loss pages worth reading: